Jiangsu Nhwa Pharmaceutical Crescita futura

Future criteri di controllo 2/6

Jiangsu Nhwa Pharmaceutical prevede che gli utili e i ricavi cresceranno rispettivamente di 17.8% e 17.2% all'anno. Si prevede che l'EPS crescerà di 17.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 17.7% in 3 anni.

Informazioni chiave

17.8%

Tasso di crescita degli utili

17.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	19.0%
Tasso di crescita dei ricavi	17.2%
Rendimento futuro del capitale proprio	17.7%
Copertura analitica	Good
Ultimo aggiornamento	14 Nov 2024

Aggiornamenti recenti sulla crescita futura

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Oct 28

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Apr 02

Recent updates

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Oct 28

Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?

Oct 21

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet

Sep 20

The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet

Sep 04

Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors

Jul 22

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly

Jun 16

Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings

May 09

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth

Apr 18

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Apr 02

Previsioni di crescita degli utili e dei ricavi

SZSE:002262 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	8,086	1,727	N/A	1,480	7
12/31/2025	6,825	1,442	N/A	1,256	8
12/31/2024	5,789	1,210	N/A	1,072	4
9/30/2024	5,531	1,171	673	1,101	N/A
6/30/2024	5,405	1,121	752	1,184	N/A
3/31/2024	5,220	1,075	529	877	N/A
12/31/2023	5,042	1,037	634	1,008	N/A
9/30/2023	4,834	1,044	719	1,039	N/A
6/30/2023	4,698	998	560	911	N/A
3/31/2023	4,485	939	585	939	N/A
1/1/2023	4,299	901	533	861	N/A
9/30/2022	4,164	867	521	813	N/A
6/30/2022	4,072	834	537	768	N/A
3/31/2022	4,024	819	505	728	N/A
1/1/2022	3,936	798	495	701	N/A
9/30/2021	3,879	830	914	1,194	N/A
6/30/2021	3,744	787	880	1,171	N/A
3/31/2021	3,528	759	981	1,270	N/A
12/31/2020	3,361	729	980	1,248	N/A
9/30/2020	3,326	714	149	325	N/A
6/30/2020	3,534	694	257	424	N/A
3/31/2020	3,837	675	237	397	N/A
12/31/2019	4,149	663	146	306	N/A
9/30/2019	4,167	623	568	727	N/A
6/30/2019	4,090	585	371	518	N/A
3/31/2019	3,981	549	341	464	N/A
12/31/2018	3,858	525	234	405	N/A
9/30/2018	3,764	472	239	431	N/A
6/30/2018	3,581	447	N/A	468	N/A
3/31/2018	3,482	411	N/A	436	N/A
12/31/2017	3,394	395	N/A	452	N/A
9/30/2017	3,274	400	N/A	384	N/A
6/30/2017	3,181	347	N/A	365	N/A
3/31/2017	3,097	325	N/A	361	N/A
12/31/2016	3,018	310	N/A	277	N/A
9/30/2016	3,004	297	N/A	263	N/A
6/30/2016	2,937	284	N/A	230	N/A
3/31/2016	2,851	269	N/A	183	N/A
12/31/2015	2,767	258	N/A	204	N/A
9/30/2015	2,694	257	N/A	140	N/A
6/30/2015	2,628	246	N/A	141	N/A
3/31/2015	2,566	235	N/A	193	N/A
12/31/2014	2,501	223	N/A	160	N/A
9/30/2014	2,418	213	N/A	218	N/A
6/30/2014	2,375	201	N/A	233	N/A
3/31/2014	2,310	186	N/A	204	N/A
12/31/2013	2,236	176	N/A	194	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 002262 ( 17.8% all'anno) è superiore al tasso di risparmio ( 2.8% ).

Guadagni vs Mercato: Si prevede che gli utili di 002262 ( 17.8% all'anno) cresceranno più lentamente rispetto al mercato CN ( 26.2% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 002262 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 002262 ( 17.2% all'anno) crescerà più rapidamente del mercato CN ( 13.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 002262 ( 17.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 002262 sarà basso tra 3 anni ( 17.7 %).

Jiangsu Nhwa Pharmaceutical Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Price target increased by 8.3% to CN¥31.30

Price target increased by 8.0% to CN¥27.29

Price target increased to CN¥22.28

Price target increased to CN¥20.24

Recent updates

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2024 Results on Oct 26, 2024

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet

The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet

Now 20% undervalued

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2024 Results on Jul 31, 2024

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly

Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth

Now 21% overvalued

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target increased by 8.3% to CN¥31.30

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2023 Results on Jul 31, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK

Price target increased by 8.0% to CN¥27.29

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target increased to CN¥22.28

Price target increased to CN¥20.24

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Insufficient new directors

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Price target decreased to CN¥16.18

Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021

Price target increased to CN¥18.01

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 02 June 2021

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥13.53

Full year 2020 earnings released: EPS CN¥0.72 (vs CN¥0.66 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.10

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day low: CN¥15.46

New 90-day high: CN¥18.50

Third quarter earnings released

Third-quarter earnings released: Earnings beat expectations, revenue disappoints

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥15.34

New 90-day low - CN¥15.61

New 90-day high - CN¥18.57

Price target raised to CN¥16.28

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2020 Results on Jul 31, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita